Table 1.

Outcomes of AML patients with and without NF1 mutations separately listed for patients aged <60 years and those aged ≥60 years

AML patients <60 years
Endpoint	NF1 mutated (n=34)a	NF1 wild-type (n=586)	P-valueb
Complete remission, n (%)	23 (68)	463 (79)	0.13
Relapse rate, n (%)	11 (50)c	276 (60)	0.38
Disease-free survival
Mutated patients (number of eventsd)	22 (15)	457 (309)	0.78
Median, years	1.5	1.4
% Disease-free at 1 year (95% CI)	59 (36-76)	57 (52-61)
% Disease-free at 3 years (95% CI)	36 (17-56)	38 (34-42)
Overall survival
Mutated patients (number of eventse)	34 (25)	586 (375)	0.12
Median, years	1.6	2.2
% Alive at 1 year (95% CI)	62 (43-76)	71 (67-75)
% Alive at 3 years (95% CI)	38 (22-54)	45 (41-49)
AML patients ≥60 years
Endpoint	NF1 mutated (n=14)a	NF1 wild-type (n=283)	P-valueb
Complete remission, n (%)	3 (21)	168 (59)	0.001
Relapse rate, n (%)	3 (100)	139 (84)	1.00
Disease-free survival
Mutated patients (number of eventsd)	3 (3)	166 (154)	–
Median, years	0.6	0.6
% Disease-free at 1 year (95% CI)	0	34 (27-41)
% Disease-free at 3 years (95% CI)	0	14 (9-20)
Overall survival
Mutated patients (number of eventse)	14 (13)	283 (266)	0.11
Median, years	0.4	0.8
% Alive at 1 year (95% CI)	14 (2-37)	41 (35-47)
% Alive at 3 years (95% CI)	14 (2-37)	15 (12-20)

Abbreviations: CI, confidence interval; n, number.

^aPatients who received allogeneic hematopoietic stem cell transplantation while in first CR (n=3) or did not receive post-remission chemotherapy according to protocol (n=1) were excluded from the outcome analyses.

^bP-values for categorical variables are from Fisher’s exact test, P-values for time to event variables are from the log-rank test.

^cOne patient who achieved a CR was lost to follow-up.

^dAn event for DFS is relapse or death, patients alive and relapse-free at last follow-up are censored.

^eAn event for OS is death and patients alive at last follow-up are censored.